Literature DB >> 12970724

Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.

B Brehmer1, S Biesterfeld, G Jakse.   

Abstract

Matrix metalloproteinases (MMPs) have been implicated in progression and metastases of different tumours. The balance between the MMPs and their natural inhibitors (tissue inhibitors of matrix metalloproteinases; TIMP) seems to be an important factor related to this role. Here, the expression of MMP-2 and -9 along with TIMP-1 and -2 was examined in prostate cancer tissue. A total of 40 radical prostatectomy specimens were embedded in paraffin and immunohistochemical staining was performed to detect MMP-2 and -9, and TIMP-1 and -2. The immunoreactivity was assessed semiquantitively using routine light microscopy. The intensity of staining was correlated to preoperative PSA, T category, Gleason score and clinical parameters of the specimens. The imbalance of MMPs and TIMPs was recognised as a significant loss of TIMP-1 in malignant epithelium and an upregulation of MMPs. Palpable tumours (T2, T3) expressed significantly more MMP-2 and significantly less MMP-9 than T1c tumours. Our data are in accordance with other literature reports in that an imbalance of MMPs and TIMPs is found in malignant tumours. The observed imbalance of MMP and TIMP is mainly caused by a loss of TIMP-1. Furthermore, palpable tumours demonstrated significantly more MMP-2 and significantly less MMP-9 expression than nonpalpable tumours.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970724     DOI: 10.1038/sj.pcan.4500657

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  31 in total

Review 1.  Myocardial matrix metalloproteinase-2: inside out and upside down.

Authors:  Ashley DeCoux; Merry L Lindsey; Francisco Villarreal; Ricardo A Garcia; Richard Schulz
Journal:  J Mol Cell Cardiol       Date:  2014-09-28       Impact factor: 5.000

2.  The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells.

Authors:  Ke-Hung Tsui; Ying-Ling Chang; Pei-Shan Yang; Chen-Pang Hou; Yu-Hsiang Lin; Bing-Wei Lin; Tsui-Hsia Feng; Horng-Heng Juang
Journal:  Cell Prolif       Date:  2017-12-21       Impact factor: 6.831

3.  Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells.

Authors:  Abeer Alasmari; Shih-Chun Lin; Serge Dibart; Erdjan Salih
Journal:  Clin Exp Metastasis       Date:  2016-05-07       Impact factor: 5.150

Review 4.  Steps in prostate cancer progression that lead to bone metastasis.

Authors:  Jung-Kang Jin; Farshid Dayyani; Gary E Gallick
Journal:  Int J Cancer       Date:  2011-03-28       Impact factor: 7.396

5.  MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells.

Authors:  Robert Steele; Justin L Mott; Ratna B Ray
Journal:  Genes Cancer       Date:  2010-04-01

6.  Piceatannol inhibits MMP-9-dependent invasion of tumor necrosis factor-α-stimulated DU145 cells by suppressing the Akt-mediated nuclear factor-κB pathway.

Authors:  Rajapaksha Gendara Prasad Tharanga Jayasooriya; Yong-Gab Lee; Chang-Hee Kang; Kyoung-Tae Lee; Yung Hyun Choi; Sung-Yong Park; Jae-Kwan Hwang; Gi-Young Kim
Journal:  Oncol Lett       Date:  2012-10-12       Impact factor: 2.967

Review 7.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

8.  A role for STEAP2 in prostate cancer progression.

Authors:  Helen Whiteland; Samantha Spencer-Harty; Claire Morgan; Howard Kynaston; David Hywel Thomas; Pradeep Bose; Neil Fenn; Paul Lewis; Spencer Jenkins; Shareen H Doak
Journal:  Clin Exp Metastasis       Date:  2014-09-24       Impact factor: 5.150

9.  Characterization and Evidence of the miR-888 Cluster as a Novel Cancer Network in Prostate.

Authors:  Tsuyoshi Hasegawa; Garrison J Glavich; Mary Pahuski; Aleena Short; O John Semmes; Lifang Yang; Vitold Galkin; Richard Drake; Aurora Esquela-Kerscher
Journal:  Mol Cancer Res       Date:  2018-01-12       Impact factor: 5.852

10.  Study of matrix metalloproteinases and their inhibitors in prostate cancer.

Authors:  S Escaff; J M Fernández; L O González; A Suárez; S González-Reyes; J M González; F J Vizoso
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.